Announcement • May 26
Novacyt S.A., Annual General Meeting, Jun 30, 2026 Novacyt S.A., Annual General Meeting, Jun 30, 2026. Location: hotel hilton paris charles de gaulle aeroport, paris France Announcement • May 21
Novacyt S.A. Launches Yourgene Insight DPYD Assay Novacyt S.A. announced the launch of Yourgene Insight DPYD assay, an assay utilizing genetic Insights for safer chemotherapy treatments to align with updated testing guidelines. Yourgene Insight DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colorectal, head and neck, breast, pancreatic and stomach cancers. Over two million cancer patients globally are treated with fluoropyrimidines (including 5-FU) each year; 10-20% of these patients suffer severe, and sometimes fatal side effects associated with DPD deficiency. Screening patients for DPYD variants allows treatments to be adjusted accordingly. Following updated guidelines from a joint consensus of organizations such as AMP (Association for Molecular Pathology) and ACMG (American College of Medical Genetics and Genomics), the 2019 original Yourgene DPYD test has been enhanced to enable the number of variants to be detected to increase from six to 19, including the 14 recommended by these updated guidelines. The product has been launched for Research Use Only (RUO) initially with In Vitro Diagnostic Regulation (IVDR) and other regulatory territory approvals to follow in due course. Many countries have already implemented DPYD genotyping ahead of prescribing chemotherapy treatment and there is a mixed model of private pay and reimbursement. The Yourgene Insight DPYD test has the same workflow and format as the original DPYD kit, with ready-to-use reagents, simple data interpretation to identify the presence or absence of 19 variants and a fast turnaround time enabling results to be provided the same day, ensuring there is no delay in patients starting their chemotherapy treatment. The Company has continued to invest in research and development to expand its product portfolio, and it is encouraging to see this investment translating into commercially launched products and tangible pipeline progress. Announcement • May 10
Novacyt S.A. Announces Departure of Chief Scientific Officer and Board Member Dr Joanne Mason, Effective 7 May 2026 Novacyt S.A. announces that Dr Joanne Mason is stepping down as Chief Scientific Officer and a member of the Board of Novacyt, with immediate effect, to enable her to pursue other business opportunities. Announcement • May 02
Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026 Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year. Announcement • Apr 08
Novacyt S.A. to Report Fiscal Year 2025 Results on Apr 30, 2026 Novacyt S.A. announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026 Announcement • Mar 03
Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million. Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,961,840
Price\Range: €0.4
Transaction Features: Rights Offering Announcement • Jan 21
Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025 Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025
For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million. Announcement • Oct 22
Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026 Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument.
For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26). Announcement • Sep 18
Novacyt S.A. to Report First Half, 2025 Results on Sep 30, 2025 Novacyt S.A. announced that they will report first half, 2025 results on Sep 30, 2025 Announcement • Jul 16
Novacyt S.A. Announces the Launch of LightBench® Discover Novacyt S.A. announced the launch of LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. The concept for the LightBench® Discover was developed following a close collaboration with PacBio®, where Yourgene Health became a PacBio® Compatible Partner for the original LightBench®? in November 2023. As part of product development for LightBench® Discover, Novacyt deployed prototype instruments into the field to gather customer feedback on user experience, develop protocols and run real world samples to assess the instruments' performance. LightBench® Discover is an integrated single benchtop solution that replaces the need for multiple instruments in labs conducting long-read HiFi sequencing, who need both large fragment analytics (larger than 20 kilobases) and DNA size selection. In addition, LightBench®? Discover also delivers fluorometric quantification. Researchers benefit from a cost-effective, high-performance system that enhances efficiency, whilst eliminating the need to invest in multiple instruments with separate service contracts and software platforms. The product has extended capabilities (compared to the original LightBench®) for large fragment analytics up to 150 kilobases, along with size selection and quantification functions, making it ideal for research applications utilising long read sequencing on the PacBio Revio®? or Vegatm systems. The Company has released the Technical Note showcasing data from its collaborator The CoLab at the HudsonAlpha Institute for Biotechnology in Alabama, US. The Technical Note will be hosted on the Company's website <URL> and on the PacBio®? Compatible Partners webpage. Announcement • May 15
Novacyt S.A., Annual General Meeting, Jun 19, 2025 Novacyt S.A., Annual General Meeting, Jun 19, 2025. Location: hotel hilton paris charles de gaulle aeroport, velizy villacoublay France Announcement • Apr 22
Novacyt S.A. to Report Fiscal Year 2024 Results on Apr 30, 2025 Novacyt S.A. announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Apr 30, 2025 Announcement • Feb 22
Novacyt S.A. Announces IVDR Accreditation for Yourgene®? QST*R Base Assay Novacyt S.A. announced that it has receivedaccreditation under the new EU requirements of theIn VitroDiagnostic Regulation ("IVDR") for theYourgene® QSTRBaseassay.TheYourgene® QSTRBaseis a Class Cin vitromedical device under IVDR and is intended for use by healthcare professionals within a molecular laboratory environment. Yourgene® QSTR Base is a highly multiplexed, single tube assay containing 22 markers for rapid diagnosis of the common autosomal and sex chromosome aneuploidies during pregnancy. For those women identified as being at high risk of carrying a fetus with one of these conditions, chorionic villus sampling (10-12 weeks) or amniocentesis (14-18 weeks) is offered and QSTR Base would then be used by the laboratory. Autosomal markers are used to detect the three most common viable autosomal trisomies: trisomy 21 (Down's syndrome), trisomy 18 (Edwards' syndrome) and trisomy 13 (Patau's syndrome). The chosen markers are highly informative with results obtained in >99% of samples. IVDR ensures that the Yourgene® QSTR Base assay, which is manufactured for sale in the EU, is assessed against stringent quality, safety and performance requirements. Manufacturers must provide considerable evidence of scientific validity, as well as data demonstrating analytical and clinical performance of the tests. The Yourgene® QSTR Base assay was assessed by British Standards Institution (BSI), an independent conformity assessment body, and was shown to conform to the new regulations. Announcement • Oct 08
Novacyt S.A. Closure of IT-IS International Limited Novacyt S.A. announced the closure of its IT-IS International Limited ("IT-IS") subsidiary, effective immediately. IT-IS, a Stokesley-based manufacturer of rapid-PCR instruments, was acquired by Novacyt in 2020 to support the Group's response to COVID-19, where it facilitated the full delivery of the Group's contracts during the period. The PCR instrumentation market has since become saturated, with IT-IS subsequently experiencing several consecutive loss-making years. IT-IS contributed £0.3m to the Group's total revenue in H1 2024 (H1 2023: £0.6million). The Intellectual Property ("IP") that exists within IT-IS will be retained to allow Novacyt to continue an ongoing IP infringement dispute with Roche Diagnostics GmbH. The dispute, instigated by IT-IS, dates back over five years and is currently progressing through the German courts. The Group will provide further updates on the dispute when appropriate. Reported Earnings • Sep 27
First half 2024 earnings released: UK£0.25 loss per share (vs UK£0.12 loss in 1H 2023) First half 2024 results: UK£0.25 loss per share (further deteriorated from UK£0.12 loss in 1H 2023). Revenue: UK£10.3m (up 209% from 1H 2023). Net loss: UK£17.7m (loss widened 118% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Announcement • Sep 26
Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024 Novacyt S.A. announces the appointment of Dr. John Brown CBE as Chairman effective from 1 October 2024. Dr. Brown was appointed Non-executive Director of Novacyt in September 2023 following the acquisition of Yourgene Health and will succeedJames Wakefield, who is retiring from the Board having been Chairman since before the company joined AIM in 2017. Dr. Brown has over 38 years industry experience, which includes significant capital markets and board experience in the healthcare and life sciences sector. He is currently Chairman of Laverock Therapeutics Ltd. and Calcivis Ltd, and until recently was Chairman of Synpromics Ltd, BioCity Group and the Cell and Gene Therapy Catapult. Previously, he was Chairman of Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd. and CXR Biosciences Ltd. and Senior Non-Executive Director of Quantum Pharma plc. Dr. Brown was appointed to the Board of Yourgene Health in July 2019 as a Non-executive Director and became Chairman in April 2022. New Risk • Sep 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 30% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Market cap is less than US$100m (€56.3m market cap, or US$62.5m). Announcement • Sep 12
Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024 Novacyt S.A. announced that they will report first half, 2024 results on Sep 26, 2024 Announcement • May 22
Novacyt S.A., Annual General Meeting, Jun 26, 2024 Novacyt S.A., Annual General Meeting, Jun 26, 2024. Location: velizy villacoublay France Announcement • May 21
Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024 Novacyt S.A. announced that they will report fiscal year 2023 results on May 30, 2024 Board Change • May 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Juliet Thompson was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 01
Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed Novacyt S.A. noted the judgment by Mrs. Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs. Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment. The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024. New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (€41.8m market cap, or US$44.5m). Reported Earnings • Oct 02
First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022) First half 2023 results: UK£0.12 loss per share (further deteriorated from UK£0.071 loss in 1H 2022). Net loss: UK£8.14m (loss widened 61% from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance. New Risk • Sep 29
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€48.0m market cap, or US$50.7m). Announcement • Sep 13
Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023 Novacyt S.A. announced that they will report Q2, 2023 results on Sep 28, 2023 Announcement • Jul 28
Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023 Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19). New Risk • Jul 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Market cap is less than US$100m (€33.9m market cap, or US$36.8m). Announcement • May 10
Novacyt S.A., Annual General Meeting, Jun 15, 2023 Novacyt S.A., Annual General Meeting, Jun 15, 2023, at 14:00 Central European Standard Time. Reported Earnings • Apr 28
Full year 2022 earnings released: UK£0.31 loss per share (vs UK£0.14 loss in FY 2021) Full year 2022 results: UK£0.31 loss per share (further deteriorated from UK£0.14 loss in FY 2021). Revenue: UK£21.0m (down 78% from FY 2021). Net loss: UK£22.2m (loss widened 128% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 54% per year whereas the company’s share price has fallen by 51% per year. Buying Opportunity • Feb 08
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 5.4%. The fair value is estimated to be €0.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 34% over the last 3 years. Meanwhile, the company became loss making. Announcement • Jan 26
Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023 Novacyt S.A. announced that they will report fiscal year 2022 results on Apr 24, 2023 Buying Opportunity • Dec 15
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be €1.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 34% over the last 3 years. Meanwhile, the company became loss making. Announcement • Oct 26
Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation Novacyt announced that the company’s genesig® Real-Time PCR SARS-CoV-2 Winterplex® 3G assay panel (Winterplex® 3G) has been approved in the UK under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA"), making it the company’s sixth PCR test to be added to the CTDA register of approved COVID-19 diagnostic products. Winterplex® 3G is a high throughput multiplex screening assay (with 96 reactions per kit) for the detection of influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 (COVID-19) (specifically the detection of ORF1ab, S and M genes targets) from oropharyngeal, nasopharyngeal or sputum samples. This approval comes in advance of the winter virus season in the northern hemisphere and means the Company can now sell Winterplex® 3G in the UK. Winterplex® 3G allows healthcare systems to differentiate between common respiratory infections which present with similar symptoms. As the prevalence of winter viruses increases, Novacyt continues to monitor all strains of influenza A, influenza B, RSV and SARS-CoV-2 through its bioinformatics surveillance programme. Buying Opportunity • Oct 12
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 31%. The fair value is estimated to be €1.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 34% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Sep 30
First half 2022 earnings released: UK£0.07 loss per share (vs UK£0.18 loss in 1H 2021) First half 2022 results: UK£0.07 loss per share (improved from UK£0.18 loss in 1H 2021). Revenue: UK£16.5m (down 69% from 1H 2021). Net loss: UK£5.04m (loss narrowed 60% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 164% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 29
Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022 Novacyt S.A. provided group financial guidance for the third quarter and year-to-date ended September 2022 and fourth quarter of 2022. Group revenue for third quarter 2022 is expected to be circa £2.0 million bringing the year-to-date revenue to £18.5 million at the end of September 2022. The Board expects fourth quarter 2022 revenue to be similar to third quarter 2022. Announcement • Sep 15
Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022 Novacyt S.A. announced that they will report first half, 2022 results on Sep 29, 2022 Announcement • Aug 05
Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays Novacyt announced the launch of the company’s first fully lyophilised (freeze-dried), direct-to-PCR assays. This new class of PROmate® assay enables shipping and transportation at ambient temperatures to remote regions or in areas without a centralised cold storage supply chain, providing an extended global reach for Novacyt’s PCR portfolio. The first two lyophilised, direct-to-PCR assays to be launched are PROmate® COVID-19 (q32) 2G Dry and PROmate® COVID-19 (q16) 2G Lite Dry, further expanding Novacyt’s COVID-19 detection portfolio and meeting customer distribution requirements for assays which can be deployed more easily in remote or developing regions. These new assays complement Novacyt’s COVID-19 variant detection portfolio, with a broader portfolio of lyophilised direct-to-PCR assays in development for the detection of other infectious diseases. Both PROmate® COVID-19 (q32) 2G Dry and PROmate® COVID-19 (q16) 2G Lite Dry are based on the PROmate® COVID-19 direct-to-PCR chemistry, and target the ORF1ab gene and the nsp16 gene, a non-structural protein of SARS-CoV-2. They are designed to function as a total workflow solution PCR amplification and analysis, with PROmate® COVID-19 (q32) 2G Dry configured for use on the Company’s q32 instrument, and PROmate® COVID-19 (q16) 2G Lite Dry configured for use on the company’s q16 instrument. Announcement • Jul 28
Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay Novacyt S.A. announces the launch of a research-use-only (RUO) polymerase chain reaction (PCR) assay for the detection of adenovirus F41, in response to recent cases of acute hepatitis in children. This launch expands Novacyt’s genesig® real-time PCR diagnostic product portfolio and is in line with the Company’s strategy to maintain its position as a global first responder in infectious diseases. Adenoviruses are a large group of viruses divided into several species and subtypes. They are the cause of several illnesses, usually exhibiting as colds or flu-like illness, which may also cause gastrointestinal symptoms such as diarrhoea. Adenoviruses are primarily spread via respiratory droplets; however, they can also be spread by faecal routes. Ongoing investigations, particularly in the UK, have identified adenovirus infection in children, and in particular, adenovirus F41 in several cases. This assay has been developed in two forms, genesig® Advanced and genesig® Easy, designed for in vitro detection of adenovirus species F serotype 41 genomes, without detecting any closely related adenovirus sequences. Novacyt’s genesig® Advanced assay is configured for use with any open test platform, including Novacyt’s MyGo instruments, the genesig® Easy assay is suitable for use on the Company’s q16 and q32 instruments. Announcement • Jul 15
Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK Novacyt announced that the Company's exsig COVID-19 Direct Real-Time PCR test has been approved in the UK under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA"). The exsig COVID-19 Direct Real-Time PCR test is designed to detect a SARS-CoV-2 gene target within ORF1ab and, as with all the Company's direct-to-PCR products, removes the need for manual or automated extraction solutions to significantly improve laboratory workflow and reduce costs. In addition, the test is designed for use on an open platform, meaning it can be used with the Company's q16 and q32 instruments, as well as other validated systems. The test is the Company's fifth PCR product to be added to the CTDA register of approved products. Announcement • Jun 29
Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries Novacyt announced the launch of its research-use-only (RUO) polymerase chain reaction (PCR) monkeypox assay in response to the recent outbreak of the virus in non-endemic countries. The launch of this assay expands Novacyt’s genesig® real-time PCR diagnostic product portfolio and is in line with the company’s strategy to maintain its position as a global first responder in infectious diseases. Monkeypox is a rare viral disease, which predominantly occurs in Central and Western Africa. The monkeypox virus is zoonotic meaning transmission is primarily between animals and humans, but human-to-human transmission can also occur, through contact with skin lesions, body fluids and respiratory secretions of infected animals or humans. Clinical presentations in humans are similar to smallpox with fever, headache, swollen lymph nodes, fatigue, and muscle aches along with characteristic pox lesions. Novacyt’s RUO monkeypox assay has been developed in two forms, genesig® easy and genesig® advanced, for detection of the virus genome (both West African and Central African variants). Both forms analyse DNA extracted from serum, lesion exudate, or scab samples from human or animal species. The genesig® advanced assay is designed to be used with any open test platform, including Novacyt’s MyGo instruments, whilst the genesig® easy assay is suitable for use on the Company’s q16 and q32 instruments. The advanced assay is quantitative if run alongside the recommended standard curve but can also be run without one and still give a qualitative result. The easy kit (q16 and q32 only) does not need a standard curve, instead software analyses the results of the sample and control to give a semi-quantitative result. Announcement • May 13
Novacyt S.A., Annual General Meeting, Jun 21, 2022 Novacyt S.A., Annual General Meeting, Jun 21, 2022, at 14:00 Central European Standard Time. Reported Earnings • Apr 29
Full year 2021 earnings released: UK£0.14 loss per share (vs UK£1.94 profit in FY 2020) Full year 2021 results: UK£0.14 loss per share (down from UK£1.94 profit in FY 2020). Revenue: UK£95.8m (down 65% from FY 2020). Net loss: UK£9.73m (down 107% from profit in FY 2020). Over the next year, revenue is expected to shrink by 59% compared to a 43% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has increased by 118% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 26
Novacyt S.A. Provides Update on DHSC Dispute Novacyt announced an update on its ongoing dispute with the Department of Health and Social Care (“DHSC”). On 9 April 2021, Novacyt announced it was in dispute with the DHSC regarding its second supply contract, announced on 29 September 2020. On 25 April 2022, the Company was notified that the DHSC has now issued a claim against Primerdesign Ltd. and Novacyt S.A. for £134.6 million relating to this contract. The claim amount is broadly in line with the disputed in fourth quarter of 2020 revenue, as previously announced by the Company. Announcement • Apr 12
Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation Novacyt announced that the Company's PROmate® COVID-19 1G (q32) Real-Time PCR test has been approved in the UK under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA"). The PROmate® COVID-19 1G test for use on Novacyt's q32 instrument is the Company's second direct-to-PCR and third product to be added to the CTDA register of approved products. The test is designed to detect a SARS-CoV-2 gene target within ORF1ab and, as with all the Company's direct-to-PCR products, removes the need for complex, manual, or automated extraction solutions to significantly improve laboratory workflow and reduce costs. The test was previously on the CTDA Temporary Protocol list of products which can continue to be sold in the UK whilst validation is being processed. As previously announced, Novacyt's PROmate® COVID-19 1G test for use on the Company's q16 instrument (currently on the Temporary Protocol list) continues to be supplied to the NHS under a National Microbiology Framework. Recent Insider Transactions • Mar 28
CEO & Director recently bought €121k worth of stock On the 25th of March, David Allmond bought around 44k shares on-market at roughly €2.77 per share. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months. Announcement • Feb 17
Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation Novacyt S.A. announced that the company's PROmate COVID-19 2G real-time PCR test has been approved in the UK under the UK health security agency's medical devices (coronavirus test device approvals) (amendment) regulations 2021 (CTDA). The PROmate COVID-19 2G test is the first direct-to-PCR product to be added to the CTDA register of approved products and is designed to detect two SARS-CoV-2 targets within ORF1ab in response to an increasing shift from single-gene to multi-gene testing solutions. Direct-to-PCR products remove the need for complex, manual or automated extraction solutions and are designed to significantly improve laboratory workflow and reduce costs. It also allows testing to take place away from traditional, laboratory-based settings due to simplicity and ease of use. Therefore, the PROmate COVID-19 2G PCR test is well suited for industries such as travel, sport, film, media, and workplace settings. The validation of the PROmate COVID-19 2G test follows the UK approval of the company's COVID-19 genesig real-time PCR test under the CTDA, as announced on November 26, 2021. In addition, as previously announced, Novacyt's PROmate COVID-19 1G real-time PCR test, currently being supplied to the NHS under a national microbiology framework, remains on the temporary protocol list (due to expire on February 28, 2022) and the company awaits further updates on an additional seven products submitted to the CTDA across its COVID-19 testing portfolio. Announcement • Feb 02
Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022 Novacyt S.A. announced that they will report fiscal year 2021 results on Apr 25, 2022 Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment improved over the past week After last week's 19% share price gain to €4.37, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 1,003% over the past three years. Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment deteriorated over the past week After last week's 20% share price decline to €4.08, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 986% over the past three years. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improved over the past week After last week's 28% share price gain to €3.26, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 36x in the Biotechs industry in Europe. Total returns to shareholders of 817% over the past three years. Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment improved over the past week After last week's 15% share price gain to €3.37, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 36x in the Biotechs industry in Europe. Total returns to shareholders of 762% over the past three years. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improved over the past week After last week's 34% share price gain to UK£4.57, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 22x in the Biotechs industry in Europe. Total returns to shareholders of 40% over the past year. Announcement • Aug 19
Novacyt S.A. Reiterate Revenue Guidance for the Full Year Novacyt S.A. reiterates revenue guidance of £100 million for the full year, excluding DHSC revenues, as announced on 22 June 2021. Reported Earnings • Jun 23
Full year 2020 earnings released: EPS UK£1.94 (vs UK£0.072 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£277.2m (up UK£266.1m from FY 2019). Net income: UK£132.4m (up UK£135.7m from FY 2019). Profit margin: 48% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Announcement • Jun 22
Novacyt S.A. Provides Sales Guidance for the Full Year 2021 If demand picks up in line with expectations, Novacyt S.A. expects to see full year 2021 sales of approximately £100 million, excluding the sales to the DHSC which are in dispute. Announcement • Jun 03
Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios Novacyt announced the launch of two new polymerase chain reaction (PCR) assays, expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 variant detection portfolios. genesig® COVID-19 3G is a CE-Marked three-gene assay to detect the ORF1ab, M gene, and S gene targets of SARS-CoV-2, enabling fulfilment of certain international testing requirements, including Fit to Fly Certificate, Test to Release and US Food and Drug Administration regulations. SNPsig® EscapePLEX SARS-CoV-2 is a first-to-market assay panel in a single kit able to detect the four most critical SARS-CoV-2 mutations currently recognised, combined with a confirmatory two-gene assay for COVID-19. The research-use-only kit detects the biologically significant ‘escape’ mutations E484K, K417N, K417T and P681R, present in the Alpha, Beta, Gamma and Delta Variants of Concern (VoC), and also incorporates the two gene (ORF1ab and M) assay to provide a confirmatory detection of SARS-CoV-2. Novacyt’s genesig® portfolio is a well-established range of PCR kits for pathogen detection. The new three-gene assay for COVID-19 has been developed in recognition of rapidly changing testing needs dictated by SARS-CoV-2 mutations and complements the Company’s existing one-gene, two-gene, and high-throughput tests. The Company aims to capture a wider share of the growing global travel market for COVID-19 testing with the three-gene test. The SNPsig® portfolio is initially focused on detecting the most significant mutations, VoC and variants of SARS-CoV-2 and currently includes 13 assays. The Company believes the SNPsig® EscapePLEX SARS-CoV-2 will be crucial in helping clinicians and public healthcare centres globally identify SARS-CoV-2 mutations which can impact transmissibility, immunity, and infection severity. Announcement • May 26
Novacyt S.A. Announces Launch of VersaLab™ Portable Novacyt S.A. announces the expansion of its VersaLab™ portfolio with the launch of VersaLab™ Portable to provide an additional level of support in near-patient testing environments. VersaLab™ was launched in December 2020 to support private sector testing of infectious diseases, initially focused on COVID-19. Novacyt added to the VersaLab™ portfolio in March 2021 with the launch of VersaLab™ mobile processing laboratories. Novacyt believes that VersaLab™ Portable is an important addition to its commercial strategy as the Company looks to expand its reach in private sector testing, especially in overseas markets. The product is a “PCR lab in a box” and as such comes with all the equipment required to provide near-patient PCR testing using Novacyt’s PROmate™ workflow in non-clinical settings, such as offices and workplaces. VersaLab™ Portable has been designed specifically with a focus on small to medium organisations, which represent a growing market opportunity for Novacyt. Other potential applications include sport events and facilities, education facilities, the leisure industry, humanitarian bases and retail. PROmate™ is the only rapid direct-to-PCR COVID-19 assay approved by the Department of Health and Social Care’s Technology Validation Group. PROmate’s™ unique workflow allows Novacyt to provide rapid results to patients in under 80 minutes, saving time and minimising the risk of infection spreading. Valuation Update With 7 Day Price Move • May 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €3.98, the stock trades at a forward P/E ratio of 2x. Average forward P/E is 35x in the Biotechs industry in Europe. Total returns to shareholders of 16% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.22 per share. Announcement • May 17
Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range Novacyt announced that the Company’s SNPsig SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England Framework for detecting Variants of Concern (VoC). Novacyt also announces the launch of two new PCR assays to detect SARS-CoV-2 VoC. Detecting known VoC Framework, announced by NHS England on 14 May 2021, includes the Company’s SNPsig SARS-CoV-2 PCR genotyping portfolio as one of the four companies selected by NHS England. This national framework is for testing of all positive SARS-CoV-2 samples from NHS (pillar 1) and high throughput Lighthouse (pillar 2) laboratories in England. SNPsig COVID-19 (20I/501Y.V1 + E484K) is a CE Marked assay to detect 20I/501Y.V1, the VoC originally identified in the UK, VOC-21FEB-02 and all SARS-CoV-2 variants carrying the E484K escape mutation. SNPsig SARS-CoV-2 (E484K) Easy is a research-use-only, streamlined workflow solution for the detection of SARS-CoV-2 variants carrying the E484K escape mutation for use with the Company’s q32 rapid-PCR instrument. This assay comes with pre-filled cassettes and includes only one pipetting step to decrease operator complexity and improve cycle times. Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment improved over the past week After last week's 28% share price gain to €5.90, the stock trades at a forward P/E ratio of 3x. Average forward P/E is 36x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.55 per share. Announcement • Apr 11
Novacyt S.A. Provides Earnings Guidance for the Year 2021 Novacyt S.A. provided earnings guidance for the year 2021. The company believe revenue and profit for 2021 may be lower than current market expectations due to the absence of the DHSC contract extension. Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment deteriorated over the past week After last week's 38% share price decline to €5.05, the stock trades at a trailing P/E ratio of 7.8x. Average forward P/E is 34x in the Biotechs industry in Europe. Total returns to shareholders of 17% over the past year. Is New 90 Day High Low • Feb 25
New 90-day low: €7.80 The company is down 9.0% from its price of €8.58 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.95 per share. Announcement • Feb 02
Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants Novacyt announced the launch of a new and innovative portfolio of assays (under the brand name SNPsig) to aid the diagnosis of the new variants of SARS-CoV-2. Novacyt'ss existing polymerase chain reaction (PCR) COVID-19 portfolio remains highly accurate in detecting all published SARS-CoV-2 variants. The launch of the new SNPsig® portfolio complements and expands the Company's offering into the rapidly evolving requirement for PCR genotyping of variants. As noted by the US Centers for Disease Control and Prevention, multiple SARS-CoV-2 variants emerged in late 2020. The three most notable variants were originally identified by their reporting origin, the UK (20I/501Y.V1 or B.1.1.7), South Africa (20H/501Y.V2 or B.1.351) and Brazil (20J/501Y.V3 or B.1.1.28) but are now prevalent globally1. The emergence of these variants has been reported across Europe, in 32 US states2, Japan, Africa and Latin America and is expected to significantly impact the clinical care of individual patients, local community disease control and national epidemiological strategies3, due to suggested evidence that these variants are associated with an increase in mortality and transmission4. The tracking of variants could also contribute to the effectiveness of vaccination efforts, especially if, as described in recent publications, the emergence of variants may have an impact on vaccine efficaciousness5. The SNPsig assays offer the ability to track variants on-site and to generate a result in hours, compared to the current approach of next generation sequencing, which is typically constrained by limited capacity, cost and an off-site multi-day turnaround. Novacyt's bioinformatics surveillance group has worked with a global network of virologists tracking variants to identify the mutations, or Single Nucleotide Polymorphisms (SNPs), critical to each variant. From this analysis, Novacyt has developed and patented the SNPsig portfolio, which is one of the first commercially available for variant detection. The first three SNPsig assays enable the identification of the non-variant virus and the UK, South Africa or Brazil variants, as well as any variant carrying the N501Y mutation. The next product in the SNPsig portfolio, planned to launch shortly, will be an assay panel, known as VariPLEX, to detect these three variants and two other key mutations identified by the World Health Organization6 in a single test. Novacyt's bioinformatics surveillance group remains highly vigilant and, as significant new mutations are identified, these will be added to the SNPsig portfolio. The SNPsig assays are designed to run on central laboratory systems and on the Company's q16 and q32 rapid PCR systems as research-use-only products. The Company expects to launch the regulatory approved clinical diagnostic assays next month. Of note, the first three SNPsig assays are also being deployed to an international consortium of leading academic and public health laboratories in the UK, Europe, US and Latin America7, assembled by Novacyt to support a global variant diagnostic surveillance study. Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment deteriorated over the past week After last week's 20% share price decline to €10.00, the stock is trading at a trailing P/E ratio of 15.9x, down from the previous P/E ratio of 19.9x. This compares to an average P/E of 40x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 2,132%. Is New 90 Day High Low • Jan 26
New 90-day high: €13.26 The company is up 44% from its price of €9.22 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.79 per share. Valuation Update With 7 Day Price Move • Jan 15
Investor sentiment improved over the past week After last week's 22% share price gain to €11.30, the stock is trading at a trailing P/E ratio of 18x, up from the previous P/E ratio of 14.8x. This compares to an average P/E of 43x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 7,025%. Announcement • Jan 06
Novacyt S.A. Announces Board Changes Novacyt announces that Anthony Dyer has taken on a new role as Chief Corporate Development Officer (CCDO). Appointment is with immediate effect. Anthony Dyer will remain a Board Director until James McCarthy is elected to the Board. Most recently he was CFO of Flint Group, a $2.5 billion revenue, PE backed business with 7,900 staff and 180 sites across 40 countries. Previously, he was CFO of Brambles Plc’s EMEA CHEP business before being promoted to President of CHEP’s European team. Brambles Plc is an Australian-based, ASX listed business with a market capitalisation of AUD 16 billion. Announcement • Jan 05
Novacyt S.A. Appoints James McCarthy as Chief Financial Officer Novacyt S.A. announced that James McCarthy has been appointed as Chief Financial Officer (CFO), with immediate effect. James has held a number of senior positions in major listed and private equity-backed businesses. Most recently he was CFO of Flint Group, a $2.5 billion revenue, PE backed business with 7,900 staff and 180 sites across 40 countries. Previously, he was CFO of Brambles Plc's EMEA CHEP business before being promoted to President of CHEP's European team. Announcement • Dec 14
Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza Novacyt announced the launch of its research-use-only (RUO) polymerase chain reaction (PCR) test for a new strain of COVID-19 and the development of two new RUO PCR tests for avian influenza following recent outbreaks across Europe. COVID-19: Further to the announcement on 16 November 2020, Novacyt has launched the first RUO PCR test for a specific new mutation of the SARS-CoV-2 virus, known as Y453F. Originally found in mink in Denmark and The Netherlands, the Y453F mutation quickly spread to humans and has also been detected outside of Europe. The mutation is of potential concern to scientists and clinicians as it causes an amino acid change which affects antibody binding. The Company believes this could have implications for vaccine strategies, which are predicated on stimulating a defined antibody response to the virus. While it is unknown what, if any, impact the amino acid modification will have on vaccines, Novacyt believes a RUO test could help scientists and clinicians to identify patients that carry the virus with the Y453F mutation. Should a clinical need arise for the diagnostic differentiation of Y453F from other strains of COVID-19 infection, Novacyt is well positioned to offer this as a clinical use diagnostic product. The RUO product is immediately available to order. Avian influenza: Novacyt has also taken the strategic decision to develop two new RUO PCR tests for avian influenza amid recent outbreaks. The European Centre for Disease Prevention and Control has announced that since October 2020, multiple European countries, including the UK and France, have reported outbreaks for highly pathogenic avian influenza (HPAI) viruses. Three different subtypes of HPAI viruses have been identified in wild birds and poultry, including A(H5N8), A(H5N5) and A(H5N1), with A(H5N8) being the most common. Given the expected movements of both migratory and resident wild birds in Europe during winter, there is a high risk of further spread of the HPAI A(H5) viruses, in particular to poultry. This has already been seen in the UK, resulting in the culling of thousands of turkeys with the H5N8 strain, including in North Yorkshire and West Norfolk. While no human infection due to these viruses has so far been detected and the threat to the general population is currently low, continued surveillance of avian influenza viruses in Europe is important to monitor virus evolution and emergence. As a result, Novacyt has developed two RUO PCR tests to assist in the current outbreaks. These include a test to detect all HPAI A(H5) subtypes and a test designed to confirm the specific presence of the HPAI A(H5N8) subtype, which has been at the centre of the current outbreaks. Both tests can be run on the Company’s mobile PCR testing instruments, q16 and q32, as well as on central laboratory-based PCR machines. Both RUO products are immediately available to order. Valuation Update With 7 Day Price Move • Dec 09
Market bids up stock over the past week After last week's 23% share price gain to €9.98, the stock is trading at a trailing P/E ratio of 15.9x, up from the previous P/E ratio of 12.9x. This compares to an average P/E of 44x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 7,636%. Valuation Update With 7 Day Price Move • Nov 17
Market bids up stock over the past week After last week's 16% share price gain to €8.75, the stock is trading at a trailing P/E ratio of 14.1x, up from the previous P/E ratio of 12.1x. This compares to an average P/E of 44x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 8,650%. Recent Insider Transactions • Nov 14
CEO & Director recently bought €558k worth of stock On the 11th of November, Graham Mullis bought around 61k shares on-market at roughly €9.17 per share. This was the largest purchase by an insider in the last 3 months. Graham has been a buyer over the last 12 months, purchasing a net total of €591k worth in shares. Valuation Update With 7 Day Price Move • Nov 10
Market pulls back on stock over the past week After last week's 30% share price decline to €8.00, the stock is trading at a trailing P/E ratio of 12.7x, down from the previous P/E ratio of 18.3x. This compares to an average P/E of 29x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 11,378%. Valuation Update With 7 Day Price Move • Nov 05
Market bids up stock over the past week After last week's 20% share price gain to €11.10, the stock is trading at a trailing P/E ratio of 17.8x, up from the previous P/E ratio of 14.8x. This compares to an average P/E of 30x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 16,718%. Valuation Update With 7 Day Price Move • Oct 31
Market pulls back on stock over the past week After last week's 17% share price decline to €10.84, the stock is trading at a trailing P/E ratio of 18x, down from the previous P/E ratio of 21.7x. This compares to an average P/E of 34x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 19,154%. Valuation Update With 7 Day Price Move • Oct 27
Market bids up stock over the past week After last week's 20% share price gain to €11.40, the stock is trading at a trailing P/E ratio of 17.2x, up from the previous P/E ratio of 14.4x. This compares to an average P/E of 34x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 24,575%. Is New 90 Day High Low • Oct 21
New 90-day high: €11.02 The company is up 266% from its price of €3.02 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 14% over the same period. Valuation Update With 7 Day Price Move • Oct 21
Market bids up stock over the past week After last week's 18% share price gain to €11.02, the stock is trading at a trailing P/E ratio of 17.3x, up from the previous P/E ratio of 14.7x. This compares to an average P/E of 35x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 24,443%. Valuation Update With 7 Day Price Move • Oct 19
Market bids up stock over the past week After last week's 19% share price gain to €10.02, the stock is trading at a trailing P/E ratio of 16.1x, up from the previous P/E ratio of 13.6x. This compares to an average P/E of 36x in the Biotechs industry in Europe. Total returns to shareholders over the past year are 22,266%. Announcement • Oct 16
Novacyt S.A. (ENXTPA:ALNOV) acquired IT-IS International Ltd. for £12 million. Novacyt S.A. (ENXTPA:ALNOV) acquired IT-IS International Ltd. for £12 million on October 15, 2020. Under the terms of the acquisition, £12 million will be paid in cash will be paid upfront by the Novacyt for the entire issued share capital of IT-IS International and for the business assets of IT-IS Life Science (Ireland) Limited. The initial consideration of £10.1 million will be reduced by £3.6 million of cash on the balance sheet of IT-IS at completion resulting in net cash consideration of £6.5 million. In addition, an earn out of up to £1.9 million in cash is payable to the directors of IT-IS over the next two years, subject to certain manufacturing targets being achieved. For the year ending December 31, 2019, IT-IS International generated revenues of £3.9 million and a net income of £0.8 million. The net assets of IT-IS and the business assets of IT-IS Life Science (Ireland) Limited that are being acquired, was £2.6 million at 30 June 2020. Matthew Johnson and Charlie Bouverat of SP Angel Corporate Finance LLP, Freddie Barnfield and James Black of Numis Securities Limited acted as financial advisors to Novacyt.
Novacyt S.A. (ENXTPA:ALNOV) completed the acquisition of IT-IS International Ltd. on October 15, 2020. Announcement • Oct 04
Novacyt Signs a New Supply Contract with the UK Department of Health and Social Care Novacyt ("Novacyt" or the "Company") announced that it has signed a new supply contract with the UK Department of Health and Social Care (DHSC) for its q16 and q32 Rapid-PCR instrument platforms, exsig® COVID-19 Direct kits and genesig® SARS-CoV-2 Winterplex kits. This is the second major contract awarded by the DHSC to Primerdesign, the Company’s wholly owned molecular diagnostics division, during the COVID-19 pandemic and follows the ongoing contract announced on 27 April 2020 for the supply of its PCR COVID-19 test. Under the terms of the contract, which is in two phases, Primerdesign will supply its products to the DHSC for up to six months. Phase one has an initial fixed term of 14 weeks with the potential to extend supply by a further 10 weeks. This first phase of the contract will involve the immediate deployment of 300 PCR instruments, related kits and support services with a minimum value of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC. The second phase of the contract, which is optional by the DHSC, allows for the provision of up to 700 additional PCR instruments, related kits and support services, as well as additional COVID-19 products from the Company’s portfolio where required. Depending upon the uptake, phase two of the contract could generate considerably more sales than the first phase. The intended use of the contract is for Novacyt to support the urgent requirement for COVID-19 testing of patients in the NHS. In addition to the provision of products, the Company will also provide training and maintenance services for the q16 and q32 instrument platforms. Novacyt has the capacity to meet the demand of both phases of this new contract, as well as to continue to build its sales across international markets. Is New 90 Day High Low • Oct 02
New 90-day high: €6.18 The company is up 107% from its price of €2.99 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 6.0% over the same period. Announcement • Sep 30
Novacyt S.A. Announces Launch of COVID-19 Antibody Test Novacyt S.A. announced that, further to the announcement on 27 July 2020, the company has launched a CE-Mark approved serology (antibody) 96-well plate ELISA (enzyme-linked immunosorbent assay) test for the detection of IgG antibodies to SARS-CoV-2 derived from plasma and serum samples. The test has been launched by Microgen Bioproducts Limited (Microgen), which is part of Novacyt's protein diagnostics division Lab21. The new antibody test complements Novacyt's existing COVID-19 product portfolio, in particular the Company's polymerase chain reaction (PCR) test for COVID-19, to provide clinicians with the diagnostic tools to detect and differentiate between active and prior SARS-CoV-2 infections in patients. The new antibody test has been validated in a study where 1,673 patient samples (112 positive samples and 1,561 negative samples) were evaluated. The test demonstrated 100% sensitivity in patients that were tested at 14 days after testing positive for COVID-19 by a PCR test. The antibody test also demonstrated 99.4% specificity. 